Biopharmaceutical classification system (BCS) class IV drugs (low-solubility low-permeability) are generally poor drug candidates, yet...
GastroPlus® Tutorial: Phase 2 Video 5 Population Simulation in GastroPlus
In this video we'll be talking about population simulations.
GastroPlus® Tutorial: Phase 2 Video 4 Solubility in GastroPlus
Learn how to integrate solubility in PBPK modeling software GastroPlus 9.7
GastroPlus® Tutorial: Phase 2 Video 3 ACAT™ model in GastroPlus
Learn how to use the Advanced Compartmental Absorption and Transit Model (ACAT) in GastroPlus 9.7
Simulations Plus Names Industry Veteran Will Frederick as Chief Financial Officer
Brings 25 years of Financial Leadership, Significant Public Company Experience, and M&A Expertise to Company
5-Fluorouracil Loaded Biogenic and Albumin Capped Gold Nanoparticles Using Bacterial Enzyme—In Vitro-In Silico Gastroplus® Simulation and Prediction
The study investigated in situ biosynthesis of albumin capped 5-fluorouracil (5-FU) loaded gold nanoparticles (NPs) using bacterial extract for enhanced...
Circulating tumor DNA analysis of metastatic renal cell carcinoma
The genomic landscape of metastatic renal cell carcinoma (RCC) is not well understood, and currently available data suggest that it is functionally distinct from that of localized...
Ocular Physiologically Based Pharmacokinetic Modeling for Ointment Formulations
The purpose of this study is to show how the Ocular Compartmental Absorption & Transit (OCAT™) model in GastroPlus® can be used to characterize ocular...
Quantitative systems toxicology (DILIsym) modeling of the acetaminophen (paracetamol) mode of action (MOA) pathway for hepatotoxicity supports that acetaminophen is not a carcinogenic hazard in humans
Acetaminophen has a long history of safe use at therapeutic doses, but can cause liver injury at very high doses
Public Workshop Summary Report on Fiscal Year 2021 Generic Drug Regulatory Science Initiatives: Data Analysis and Model‐Based Bioequivalence
On May 4, 2020, the US Food and Drug Administration (FDA) hosted an online public workshop titled “FY 2020 Generic Drug Regulatory Science...
In vitro investigation of metabolic fate of α-mangostin and gartanin via skin permeation by LC-MS/MS and in silico evaluation of the metabolites by ADMET predictor™
Mangosteen, Garciniam angostana L., is a juicy fruit commonly found in Thailand.
A Novel Eutectic-Based Transdermal Delivery System for Risperidone
This paper reports for the first time the possible formation of a novel room temperature therapeutic deep eutectic solvent (THEDES)...
Novel substituted N-benzyl(oxotriazinoindole) inhibitors of aldose reductase exploiting ALR2 unoccupied interactive pocket
Recently we have developed novel oxotriazinoindole inhibitors (OTIs) of aldose reductase (ALR2), characterized by high efficacy and selectivity.
Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models
Drug-induced liver injury (DILI) is a patient-specific, temporal, multifactorial pathophysiological process that cannot yet be recapitulated in a single in vitro model.
Statement from Cognigen’s President, Jill Fiedler-Kelly
At Cognigen, we appreciate more than ever, the global community in which we live and work and the impact each of us can...
Metabolic Profiling of Nuciferine In Vivo and In Vitro
Nuciferine (NF) is one of the main constituents of Lotus (Nelumbo nucifera) leaves which have been widely used in both food and drug formulations in China.
Solubility and Stability Enhanced Oral Formulations for the Anti-Infective Corallopyronin A
Novel-antibiotics are urgently needed to combat an increase in morbidity and mortality due to resistant bacteria.
Relevance of Physiologically Based Biopharmaceutical Modeling (PBBM) in the Approval of Generic Products
The Webinar "Relevance of Physiologically Based Biopharmaceutical Modeling (PBBM) in the Approval of Generic Products", which will be presented in Spanish
Dose Optimization in Kidney Disease: Opportunities for PBPK Modeling and Simulation
Kidney disease affects pharmacokinetic (PK) profiles of not only renally cleared drugs but also nonrenally cleared drugs.